Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Langdon

Showing results (61-70 of 83) with videos related to

Pageof 9
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|April 16, 1998
Allosteric modulation of AMPA-type glutamate receptors increases activity of the promoter for the neural cell adhesion molecule, N-CAMB D Holst, P W Vanderklish, L A Krushel, et al.
European Journal of Clinical Pharmacology|February 9, 2012
Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal diseaseTeddy Kosoglou, Walter K Kraft, Bharath Kumar, et al.
Cancer Medicine|June 7, 2014
A randomized, phase II study of the anti-insulin-like growth factor receptor type 1 (IGF-1R) monoclonal antibody robatumumab (SCH 717454) in patients with advanced colorectal cancerEdward H Lin, Heinz-Josef Lenz, Mansoor N Saleh, et al.
Diabetes, Obesity & Metabolism|August 6, 2013
Efficacy and safety of initial combination treatment with sitagliptin and pioglitazone--a factorial studyR R Henry, B Staels, V A Fonseca, et al.
Journal of the American Society of Hypertension : JASH|March 23, 2011
Efficacy and safety of the selective 11β-HSD-1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertensionSukrut Shah, Anne Hermanowski-Vosatka, Kendra Gibson, et al.
Diabetes, Obesity & Metabolism|April 5, 2013
Bone loss in the oestrogen-depleted rat is not exacerbated by sitagliptin, either alone or in combination with a thiazolidinedioneT Cusick, J Mu, B L Pennypacker, et al.
Current Medical Research and Opinion|March 25, 2011
Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trialNir Barzilai, Hua Guo, Erin M Mahoney, et al.
International Journal of Clinical Pharmacology and Therapeutics|May 8, 2014
Lack of a clinically relevant effect of sugammadex on anti-Xa activity or activated partial thromboplastin time following pretreatment with either unfractionated or low-molecular-weight heparin in healthy subjectsPieter-Jan De Kam, Annelieke C Kruithof, Marie-José van Lierop, et al.
Physical Review. E, Statistical, Nonlinear, and Soft Matter Physics|October 15, 2008
Molecular dynamics simulations of temperature equilibration in dense hydrogenJ N Glosli, F R Graziani, R M More, et al.
Endocrinology|May 19, 2011
Effects of peripherally administered neuromedin U on energy and glucose homeostasisAndrea M Peier, Kunal Desai, James Hubert, et al.
Pageof 9

Showing results (61-70 of 83) with videos related to

Sort By:
Pageof 9
Proceedings of the National Academy of Sciences of the United States of America|April 16, 1998
Allosteric modulation of AMPA-type glutamate receptors increases activity of the promoter for the neural cell adhesion molecule, N-CAMB D Holst, P W Vanderklish, L A Krushel, et al.
European Journal of Clinical Pharmacology|February 9, 2012
Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal diseaseTeddy Kosoglou, Walter K Kraft, Bharath Kumar, et al.
Cancer Medicine|June 7, 2014
A randomized, phase II study of the anti-insulin-like growth factor receptor type 1 (IGF-1R) monoclonal antibody robatumumab (SCH 717454) in patients with advanced colorectal cancerEdward H Lin, Heinz-Josef Lenz, Mansoor N Saleh, et al.
Diabetes, Obesity & Metabolism|August 6, 2013
Efficacy and safety of initial combination treatment with sitagliptin and pioglitazone--a factorial studyR R Henry, B Staels, V A Fonseca, et al.
Journal of the American Society of Hypertension : JASH|March 23, 2011
Efficacy and safety of the selective 11β-HSD-1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertensionSukrut Shah, Anne Hermanowski-Vosatka, Kendra Gibson, et al.
Diabetes, Obesity & Metabolism|April 5, 2013
Bone loss in the oestrogen-depleted rat is not exacerbated by sitagliptin, either alone or in combination with a thiazolidinedioneT Cusick, J Mu, B L Pennypacker, et al.
Current Medical Research and Opinion|March 25, 2011
Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trialNir Barzilai, Hua Guo, Erin M Mahoney, et al.
International Journal of Clinical Pharmacology and Therapeutics|May 8, 2014
Lack of a clinically relevant effect of sugammadex on anti-Xa activity or activated partial thromboplastin time following pretreatment with either unfractionated or low-molecular-weight heparin in healthy subjectsPieter-Jan De Kam, Annelieke C Kruithof, Marie-José van Lierop, et al.
Physical Review. E, Statistical, Nonlinear, and Soft Matter Physics|October 15, 2008
Molecular dynamics simulations of temperature equilibration in dense hydrogenJ N Glosli, F R Graziani, R M More, et al.
Endocrinology|May 19, 2011
Effects of peripherally administered neuromedin U on energy and glucose homeostasisAndrea M Peier, Kunal Desai, James Hubert, et al.
Pageof 9